The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Hu J, Sun Y, Cheng C, Wang S, Zuo X, Liu Y

Drug-induced eosinophilic pneumonia: a real-world data mining study of the FAERS and Vigibase database reveals potential safety signals and risk patterns.

Frontiers in medicine 2026;13 — 2026 — 1788843

Syunyaeva Z, Berghof K, Kauffmann-Guerrero D, Götschke J, Tufman A, Kahnert K

Late-onset severe pneumonitis under osimertinib.

AME case reports 2019;3;39 — 2019 — 39

Tachi H, Shiozawa T, Sakai C, Kasuga M, Nakazawa K, Morishima Y, Satoh H, Hizawa N, Sakashita S, Sekine I

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2017 08;12;e118-e120 — 2017 08 — e118-e120